title: Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
authors.forename: S
authors.initials: S
authors.lastname: Grammatico
authors.forename: L
authors.initials: L
authors.lastname: Elia
authors.forename: A L
authors.initials: AL
authors.lastname: Peluso
authors.forename: L
authors.initials: L
authors.lastname: Pedace
authors.forename: M
authors.initials: M
authors.lastname: Matarazzo
authors.forename: A
authors.initials: A
authors.lastname: Vitale
authors.forename: A
authors.initials: A
authors.lastname: Rago
authors.forename: F
authors.initials: F
authors.lastname: Pane
authors.forename: R
authors.initials: R
authors.lastname: Foà
authors.forename: G
authors.initials: G
authors.lastname: Cimino
mesh_terms: D000328:Adult; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D017354:Point Mutation / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D016315:Proto-Oncogene Proteins c-abl / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D016315:Proto-Oncogene Proteins c-abl